KalVista shares rise 20.49% intraday as Pharvaris surges on promising HAE treatment trial results.

KalVista Pharmaceuticals surged 20.49% intraday as Pharvaris' promising HAE treatment test results boosted investor sentiment. The positive clinical data for Pharvaris' drug, which targets the same genetic condition, likely spurred buying interest in KalVista, given their competitive positioning in the HAE treatment market.